Rein Therapeutics (RNTX) announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein’s lead drug candidate, LTI-03, in idiopathic pulmonary fibrosis, IPF. The preprint, titled “Inhaled LTI-03 for Idiopathic Pulmonary Fibrosis: A Randomized Dose Escalation Study.” The report describes how inhaled LTI-03 was evaluated in IPF patients to assess safety, pharmacokinetics, and biological activity. According to the authors, LTI-03 was generally well tolerated, and samples collected from treated patients showed reductions in multiple fibrosis-associated biomarkers. These biomarkers include proteins and inflammatory signals linked to disease progression, offering evidence that the drug is reaching the lung and engaging its intended targets.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX:
- Rein Therapeutics upgraded to Buy from Hold at Brookline
- Rein Therapeutics Resumes Phase 2 Trial for LTI-03
- Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
- Rein Therapeutics Secures Third Pre-Paid Advance
- Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03